Table 8.

Comparison of adverse events.

	All (n = 63)	rhGH (n = 31)	Placebo (n = 32)	p-value
None reported	36 (57.1)	19 (61.3)	17 (53.1)
Arthralgia	8 (12.7)	2 (6.5)	6 (18.8)	0.256
Myalgia	7 (11.1)	1 (3.2)	6 (18.8)	0.104
Headache	4 (6.3)	1 (3.2)	3 (9.4)	0.613
Elective surgery	10 (15.9)	6 (19.4)	4 (12.5)	0.509
Urinary issue	3 (4.8)	0 (0)	3 (9.4)	0.238
Back pain	1 (1.6)	1 (3.2)	0 (0)	0.492
Broken ribs and scapula	1 (1.6)	0 (0)	1 (3.1)	1.0
Bruising at injection site	1 (1.6)	1 (3.2)	0 (0)	0.492
Drowsiness	2 (3.2)	1 (3.2)	1 (3.1)	1.0
Dizziness	1 (1.6)	1 (3.2)	0 (0)	0.492
Dry mouth	4 (6.3)	1 (3.2)	3 (9.4)	0.613
Eye puffiness	1 (1.6)	0 (0)	1 (3.1)	1.0
Hair growth	1 (1.6)	1 (3.2)	0 (0)	0.492
Hair loss	1 (1.6)	0 (0)	1 (3.1)	1.0
Weight gain	1 (1.6)	0 (0)	1 (3.1)	1.0
Irritability	1 (1.6)	0 (0)	1 (3.1)	1.0
Numbness in extremities	1 (1.6)	0 (0)	1 (3.1)	1.0
Peripheral edema	1 (1.6)	0 (0)	1 (3.1)	1.0
Seizure	2 (3.2)	2 (6.5)	0 (0)	0.613
Greatest Action Taken				0.317
Not Applicable (N/A)	36 (57.1)	19 (61.3)	17 (53.1)
None required	15 (23.8)	9 (29)	6 (18.8)
Treatment given	7 (11.1)	1 (3.2)	6 (18.8)
Study drug temporarily stopped	2 (3.2)	0 (0)	2 (6.3)
Study drug discontinued	3 (4.8)	2 (6.5)	1 (3.1)